Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Tiziana Life Sciences Ltd TLSA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • GB • USD

SharesGrow Score
43/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Tiziana Life Sciences Ltd (TLSA) is a Biotechnology company in the Healthcare sector, currently trading at $1.29. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Valuation: TLSA trades at a trailing Price-to-Earnings (P/E) of -4.1 (S&P 500 average ~25).

Net income is $12M (loss), growing at +17.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $106,000 against $4M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 1.02 (adequate). Debt-to-assets is 0.9%. Total assets: $11M.

Analyst outlook: 2 / 3 analysts rate TLSA as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 80/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

TLSA SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 80/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TLSA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
80/100
TLSA: +0%/yr revenue is, +17.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet TLSA: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 1.02 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
TLSA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 2 / 3 analysts rate TLSA as buy (67%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.73-2.6
Volume371.71K
Avg Volume (30D)195.76K
Market Cap$76.66M
Beta (1Y)0.37
Share Statistics
EPS (TTM)-0.22
Shares Outstanding$53.34M
IPO Date2018-11-20
Employees9
CEOIvor R. Elrifi
Financial Highlights & Ratios
EBITDA$-16.62M
Net Income$-11.86M
Operating Income$-15.79M
Total Cash$3.72M
Total Debt$106K
Net Debt$-3.62M
Total Assets$11.28M
Price / Earnings (P/E)-5.9
Analyst Forecast
Rating ConsensusBuy
Analysts Covering3
Buy 67% Hold 33% Sell 0%
Company Info
CountryGB
ExchangeNASDAQ Global Market
CurrencyUSD
ISINBMG889121031

Price Chart

Track all markets on TradingView
TLSA
Tiziana Life Sciences Ltd ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.73 52WK RANGE 2.60

People Also View

IMNM
IMNM
Immunome, Inc.
$22.90
+1.24%
 CRVS
CRVS
Corvus Pharmaceuticals, Inc.
$15.25
+0.53%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
 BHVN
BHVN
Biohaven Ltd.
$10.44
+3.16%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
 COEP
COEP
Coeptis Therapeutics, Inc.
$12.44
+2.81%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message